Clinical Response of Recurrent Ganglioglioma with BRAF A598_T599insV Mutation to BRAF/MEK Inhibitors (P9-6.011)
We describe the first case of a ganglioglioma with a non-canonical activating BRAF A598_T599insV mutation in a patient with remarkable clinical response to BRAF/MEK inhibitor therapy.
Authors
- Denaly Chen (ORCID: https://orcid.org/0000-0003-3753-405X)
- Frances Chow (ORCID: https://orcid.org/0000-0001-5402-2473)
- Jeremy Reynoso (ORCID: https://orcid.org/0000-0002-4376-0101)
Institutions
- University of Southern California (US)
- Veterans Health Administration (US)
- Michigan State University (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211273
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00